Clinical Trial

A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Trial Details
NCT Number NCT07087327
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Conditions Attention-Deficit Hyperactivity Disorder(ADHD)
Enrollment 180 participants
Start Date 2025-09-16
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-23